Notice of Pre-Application Information Webinar for RFA-DA-19-029, RFA-DA-19-036, HEALthy Brain and Child Development (HEALthy BCD) Study

Notice Number: NOT-DA-19-020

Key Dates
Release Date: January 16, 2019

Related Announcements



Issued by
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Mental Health (NIMH)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Minority Health and Health Disparities (NIMHD)
Office of Behavioral and Social Sciences Research (OBSSR)
Office of Research on Women’s Health (ORWH)
Environmental Influences on Child Health Outcomes Program (ECHO)


On December 21, 2018, the NIH issued the following Funding Opportunity Announcements (FOAs)

RFA-DA-19-029 HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (Collaborative R34 Clinical Trial Not Allowed)

RFA-DA-19-036 HEAL Initiative: HEALthy Brain and Child Development Study (HEALthy BCD) (R34 Clinical Trial Not Allowed)

To assist potential applicants to the above referenced FOAs, this Notice provides the following information:

A pre-application information webinar for potential HEALthy BCD applicants will be provided on February 6, 2019.

HEALthy BCD Webinar Information

Date: February 6, 2019

Time: 1:00-2:00 pm ET

The intent of the pre-application webinar is to provide an overview of the HEALthy BCD FOAs and to address questions from potential applicants. The webinar is optional and not required for application submission. The webinar may conclude before the scheduled time depending on the number of questions.

Additional information, including a link to register for the webinar will be posted at: Following the webinar, NIDA will post the slides presented during the Webinar on the same website. Prospective applicants with inquiries concerning the FOA who are unable to participate in the Webinar are encouraged to view the summary of questions and answers after the Webinar.


FAQs will be posted on the same website with a summary of questions and answers from the webinar and may be updated with additional questions and answers without further notice.


Please direct all inquiries to:

Gayathri J. Dowling, Ph.D.
National Institute on Drug Abuse (NIDA)